SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hank who wrote (3899)8/5/2001 4:15:36 PM
From: rli123  Read Replies (2) of 5582
 
What I don't understand about the article is why the researcher didn't simply evaluate Zicam --- every "variation" away from Zicam (like spray vs. gel, and sulfate vs. gluconate) creates more uncertainty than is acceptable to everybody except the "least learned" amongst us. Perhaps one value in the study is that it possibly demonstrates that Zicam might produce novel results: you can't simply throw zinc into the nose (like was done in the study) and get good results. This study is what you might expect to see in the background section of the Zicam patent.

rli
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News